| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $19.0M | -15.7% |
| SG&A Expense | $12.5M | -9.0% |
| Operating Income | -$31.5M | +13.2% |
| Pre-tax Income | -$35.7M | +7.3% |
| Income Tax | -$1.2M | -34.6% |
| Net Income | -$34.5M | +8.3% |
| EPS (Basic) | -$0.74 | +28.2% |
| EPS (Diluted) | -$0.74 | +28.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $26.7M | -35.9% |
| Current Assets | $28.3M | -37.3% |
| Total Assets | $30.5M | -32.8% |
| Current Liabilities | $9.5M | -44.5% |
| Total Liabilities | $21.2M | -19.4% |
| Stockholders' Equity | $9.3M | -51.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$27.8M | +20.8% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $0 | +100.0% |
| Financing Cash Flow | $12.8M | -36.7% |
| Free Cash Flow | -$27.8M | +20.8% |